Loading clinical trials...
Loading clinical trials...
Phase I Clinical Study of Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery
Conditions
Interventions
Autologous dendritic cells pulsed with multiple neoantigen peptides.
Temozolomide adjuvant chemotherapy
Locations
1
China
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China
Start Date
July 30, 2021
Primary Completion Date
April 30, 2024
Completion Date
December 31, 2028
Last Updated
February 11, 2025
NCT06146725
NCT05685004
NCT07464925
NCT06193174
NCT04869449
NCT04222309
Lead Sponsor
Beijing Tiantan Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions